{"nctId":"NCT00251719","briefTitle":"Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis","startDateStruct":{"date":"2005-12"},"conditions":["Esophagitis, Reflux","Esophagitis, Peptic"],"count":2054,"armGroups":[{"label":"Dexlansoprazole MR 60 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Dexlansoprazole MR"]},{"label":"Dexlansoprazole MR 90 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Dexlansoprazole MR"]},{"label":"Lansoprazole 30 mg QD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lansoprazole"]}],"interventions":[{"name":"Dexlansoprazole MR","otherNames":["TAK-390MR","Kapidex","Dexilant"]},{"name":"Dexlansoprazole MR","otherNames":["TAK-390MR","Kapidex","Dexilant"]},{"name":"Lansoprazole","otherNames":["Prevacid","AG-1749"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject must have endoscopically confirmed erosive esophagitis as defined by the Los Angeles (LA) Classification Grading System (A-D).\n\nExclusion Criteria:\n\n* Subject has a positive Campylobacter-like organisms (CLO) test for Helicobacter (H.) pylori.\n* Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists or sucralfate, drugs with significant anticholinergic effects, misoprostol or prokinetics\n* Use of antacids \\[except for study supplied GelusilÂ®\\]\n* Need for continuous anticoagulant therapy (Blood Thinners)\n* Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus\n* History of dilatation of esophageal strictures, other than Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter)\n* Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition\n* History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer\n* Acute upper gastrointestinal (UGI) hemorrhage within 4 weeks of the Screening endoscopy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.","description":"Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A (greater than or equal to 1 mucosal break and less than 5 mm). If it doesn't meet the A criterion, it's counted as healed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":null},{"groupId":"OG001","value":"89.4","spread":null},{"groupId":"OG002","value":"84.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.","description":"Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy. Change in LA Classification grades C or D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"86.3","spread":null},{"groupId":"OG002","value":"78.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.","description":"Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades C or D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.6","spread":null},{"groupId":"OG001","value":"93.3","spread":null},{"groupId":"OG002","value":"87.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method","description":"Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null},{"groupId":"OG001","value":"94.9","spread":null},{"groupId":"OG002","value":"91.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Crude Rate Analysis.","description":"Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","spread":null},{"groupId":"OG001","value":"70.6","spread":null},{"groupId":"OG002","value":"65.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Life Table Method","description":"Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.1","spread":null},{"groupId":"OG001","value":"80.4","spread":null},{"groupId":"OG002","value":"77.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":694},"commonTop":["Diarrhoea (Excluding Infective)"]}}}